Chiron Appoints Richard Wills to Board of Directors
September 09 2004 - 9:24PM
PR Newswire (US)
Chiron Appoints Richard Wills to Board of Directors Tektronix CEO
Brings Extensive Product Development and Global Marketing
Experience to Chiron Board EMERYVILLE, Calif., Sept. 9
/PRNewswire-FirstCall/ -- Chiron Corporation (NASDAQ:CHIR) today
announced that Richard Wills, age 49, has been appointed to the
company's board of directors. Mr. Wills is chief executive officer
and chairman of the board of Tektronix Inc., a technology company
providing measurement solutions to the communications, computer and
semiconductor industries worldwide. "As a sitting CEO of a
technology-based company similar to Chiron in size and scope, Mr.
Wills brings valuable business experience and great enthusiasm to
Chiron's board of directors," said Howard Pien, Chiron's chief
executive officer and chairman of the board. "We look forward to
the contributions Richard will make as Chiron continues to execute
on its business strategy, implementing pioneering science to
improve human health worldwide." Richard Wills became president and
chief executive officer of Tektronix Inc. in 2000, after more than
20 years with the company. In his time at Tektronix, Wills has held
a variety of executive-level positions in marketing, product
development and product-line management. He played a key role in
building Tektronix's sales and marketing presence in Europe, the
company's largest market outside the United States, and in
establishing the extensive global marketing capabilities of
Tektronix in the Pacific and the United States. Tektronix
manufactures more than 1,000 products and maintains operations in
North and South America, Europe and Asia Pacific, with
manufacturing sites, development centers and distributors in more
than 20 countries worldwide. About Chiron Through its global Blood
Testing, Vaccines and BioPharmaceuticals businesses, Chiron
Corporation addresses human suffering with more than 50 diverse
products to detect, prevent and treat disease worldwide. The
company's consistent success has come from its pioneering science,
skill in delivering innovations in biotechnology and disciplined
business approach. Chiron believes that science has the power to
improve people's lives and harnesses that power to transform human
health. For more information about Chiron, please visit
http://www.chiron.com/. This year, Chiron Vaccines celebrates 100
years of advancing medicine with the anniversary of two founding
companies. In 1904, Emil von Behring and Achille Sclavo
independently started companies in Germany and Italy, respectively,
dedicated to the research, development and manufacture of vaccines
to protect humanity from infectious disease. As the fifth-largest
vaccine manufacturer in the world, Chiron remains dedicated to the
legacies of von Behring and Sclavo to prevent disease and develop
new vaccines to improve human health globally. This news release
contains forward-looking statements, including statements regarding
sales growth, product development initiatives, new product
indications, new product marketing, acquisitions, and in- and
out-licensing activities that involve risks and uncertainties and
are subject to change. A full discussion of the company's
operations and financial condition, including factors that may
affect its business and future prospects, is contained in documents
the company has filed with the SEC, including the form 10-Q for the
quarter ended June 30, 2004, and the form 10-K for the year ended
December 31, 2003, and will be contained in all subsequent periodic
filings made with the SEC. These documents identify important
factors that could cause the company's actual performance to differ
from current expectations, including the outcome of clinical
trials, regulatory review and approvals, manufacturing
capabilities, intellectual property protections and defenses,
stock-price and interest-rate volatility, and marketing
effectiveness. In particular, there can be no assurance that Chiron
will increase sales of existing products, successfully develop and
receive approval to market new products, or achieve market
acceptance for such new products. There can be no assurance that
Chiron's out-licensing activities will generate significant
revenue, nor that its in-licensing activities will fully protect it
from claims of infringement by third parties. In addition, the
company may engage in business opportunities, the successful
completion of which are subject to certain risks, including
shareholder and regulatory approvals and the integration of
operations. Consistent with SEC Regulation FD, we do not undertake
an obligation to update the forward-looking information we are
giving today. DATASOURCE: Chiron Corporation CONTACT: Chiron
Corporate Communications & Investor Relations, Media,
+1-510-923-6500, or Investors, +1-510-923-2300 Web site:
http://www.chiron.com/
Copyright
Chiron (NASDAQ:CHIR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chiron (NASDAQ:CHIR)
Historical Stock Chart
From Jul 2023 to Jul 2024